Corneal thickness and endothelial change after use of ocular hypotensive agents.
cornea
glaucoma
ocular hypotensive agents
Journal
The Kaohsiung journal of medical sciences
ISSN: 2410-8650
Titre abrégé: Kaohsiung J Med Sci
Pays: China (Republic : 1949- )
ID NLM: 100960562
Informations de publication
Date de publication:
28 May 2024
28 May 2024
Historique:
revised:
10
04
2024
received:
28
11
2023
accepted:
11
04
2024
medline:
28
5
2024
pubmed:
28
5
2024
entrez:
28
5
2024
Statut:
aheadofprint
Résumé
Corneal transplantation can restore visual function when visual impairment is caused by a corneal disease. However, this treatment is associated with the scarcity of cornea donors. The suitability of corneal donation from patients with glaucoma using ocular hypotensive agents (OHAs) is controversial. This study aimed to elucidate changes in corneal thickness, corneal endothelial cell density, and corneal endothelial cell hexagonality after OHA use in patients with primary open-angle glaucoma. We retrospectively reviewed the data of 53 glaucoma suspect eyes without OHA use and 106 primary open-angle glaucoma eyes under OHA use. All participants underwent corneal parameter assessment using SP-3000P (Topcon Corp., Tokyo, Japan) at the time of diagnosis and the final visit. The OHA dose and timing of use were recorded. The ocular hypotensive agents score (OHAS) was determined based on the number, formula, frequency, and duration of OHA use. Baseline data showed no significant differences between the two groups with and without OHA use. At the final visit, the OHA-treated group showed significantly lower corneal thickness and corneal endothelial cell density than those of the control group. A weak positive correlation between the OHAS and changes in corneal endothelial cell hexagonality was noted. However, no correlation was observed between the OHAS and changes in corneal thickness or endothelial cell density. In conclusion, patients with glaucoma and using OHAs should undergo the corneal structural properties examinations before donation to ensure the quality of donor cornea.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. The Kaohsiung Journal of Medical Sciences published by John Wiley & Sons Australia, Ltd on behalf of Kaohsiung Medical University.
Références
Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90(3):262–267.
Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311(18):1901–1911.
Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120(10):1268–1279.
Ghosh S, O'Hare F, Lamoureux E, Vajpayee RB, Crowston JG. Prevalence of signs and symptoms of ocular surface disease in individuals treated and not treated with glaucoma medication. Clin Exp Ophthalmol. 2012;40(7):675–681.
Zhang X, Vadoothker S, Munir WM, Saeedi O. Ocular surface disease and glaucoma medications: a clinical approach. Eye Contact Lens. 2019;45(1):11–18.
Gaspar R, Pinto LA, Sousa DC. Corneal properties and glaucoma: a review of the literature and meta‐analysis. Arq Bras Oftalmol. 2017;80(3):202–206.
Batawi H, Lollett IV, Maliakal C, Wellik SR, Anderson MG, Feuer W, et al. A comparative study of central corneal epithelial, stromal, and total thickness in males with and without primary open‐angle glaucoma. Cornea. 2018;37(6):712–719.
Kwon JW, Rand GM, Cho KJ, Gore PK, McCartney MD, Chuck RS. Association between corneal endothelial cell density and topical glaucoma medication use in an eye bank donor population. Cornea. 2016;35(12):1533–1536.
Flaxman SR, Bourne RRA, Resnikoff S, Ackland P, Braithwaite T, Cicinelli MV, et al. Global causes of blindness and distance vision impairment 1990‐2020: a systematic review and meta‐analysis. Lancet Glob Health. 2017;5(12):e1221–e1234.
Mathews PM, Lindsley K, Aldave AJ, Akpek EK. Etiology of global corneal blindness and current practices of corneal transplantation: a focused review. Cornea. 2018;37(9):1198–1203.
Garg P, Krishna PV, Stratis AK, Gopinathan U. The value of corneal transplantation in reducing blindness. Eye (Lond). 2005;19(10):1106–1114.
Gain P, Jullienne R, He Z, Aldossary M, Acquart S, Cognasse F, et al. Global survey of corneal transplantation and eye banking. JAMA Ophthalmol. 2016;134(2):167–173.
Gedde SJ, Vinod K, Wright MM, Muir KW, Lind JT, Chen PP, et al. Primary open‐angle glaucoma preferred practice pattern®. Ophthalmology. 2021;128(1):71–150.
Gedde SJ, Lind JT, Wright MM, Chen PP, Muir KW, Vinod K, et al. Primary open‐angle glaucoma suspect preferred practice pattern®. Ophthalmology. 2021;128(1):151–192.
Bourne RR, Taylor HR, Flaxman SR, Keeffe J, Leasher J, Naidoo K, et al. Number of people blind or visually impaired by glaucoma worldwide and in world regions 1990–2010: a meta‐analysis. PLoS One. 2016;11(10):e0162229.
Weizer JS, Stinnett SS, Herndon LW. Longitudinal changes in central corneal thickness and their relation to glaucoma status: an 8 year follow up study. Br J Ophthalmol. 2006;90(6):732–736.
Vitályos G, Kolozsvári BL, Németh G, Losonczy G, Hassan Z, Pásztor D, et al. Effects of aging on corneal parameters measured with Pentacam in healthy subjects. Sci Rep. 2019;9(1):3419.
Wirtitsch MG, Findl O, Heinzl H, Drexler W. Effect of dorzolamide hydrochloride on central corneal thickness in humans with cornea guttata. Arch Ophthalmol. 2007;125(10):1345–1350.
Zhao JC, Chen T. Brinzolamide induced reversible corneal decompensation. Br J Ophthalmol. 2005;89(3):389–390.
Almeida GC Jr, Souza SJ FE. Effect of topical dorzolamide on rabbit central corneal thickness. Braz J Med Biol Res. 2006;39(2):277–281.
Meda R, Wang Q, Paoloni D, Harasymowycz P, Brunette I. The impact of chronic use of prostaglandin analogues on the biomechanical properties of the cornea in patients with primary open‐angle glaucoma. Br J Ophthalmol. 2017;101(2):120–125.
Harasymowycz PJ, Papamatheakis DG, Ennis M, Brady M, Gordon KD. Relationship between travoprost and central corneal thickness in ocular hypertension and open‐angle glaucoma. Cornea. 2007;26(1):34–41.
Kadri R, Shetty A, Parameshwar D, Kudva AA, Achar A, Shetty J. Effect of prostaglandin analogues on central corneal thickness in patients with glaucoma: a systematic review and meta‐analysis with trial sequential analysis. Indian J Ophthalmol. 2022;70(5):1502–1512.
Kim JY, Yim HW. Effect of topical prostaglandin analogue therapy on central corneal thickness: a systematic review. J Clin Med. 2022;12(1):44.
Lopilly Park HY, Kim JH, Lee KM, Park CK. Effect of prostaglandin analogues on tear proteomics and expression of cytokines and matrix metalloproteinases in the conjunctiva and cornea. Exp Eye Res. 2012;94(1):13–21.
Eye Bank Association of America. Eye Bank Association of America Medical Standards 2022. EBCT. 2022;1:e002.
Ou TH, Lai IC, Teng MC. Comparison of central corneal thickness measurements by ultrasonic pachymetry, Orbscan II, and SP3000P in eyes with glaucoma or glaucoma suspect. Chang Gung Med J. 2012;35(3):255–262.